CRVS
Price
$3.93
Change
-$0.01 (-0.25%)
Updated
Jun 18 closing price
Capitalization
303.06M
53 days until earnings call
FULC
Price
$6.36
Change
-$0.07 (-1.09%)
Updated
Jun 18 closing price
Capitalization
343.31M
47 days until earnings call
Interact to see
Advertisement

CRVS vs FULC

Header iconCRVS vs FULC Comparison
Open Charts CRVS vs FULCBanner chart's image
Corvus Pharmaceuticals
Price$3.93
Change-$0.01 (-0.25%)
Volume$644.25K
Capitalization303.06M
Fulcrum Therapeutics
Price$6.36
Change-$0.07 (-1.09%)
Volume$390.31K
Capitalization343.31M
CRVS vs FULC Comparison Chart in %
Loading...
CRVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FULC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRVS vs. FULC commentary
Jun 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRVS is a Hold and FULC is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 20, 2025
Stock price -- (CRVS: $3.93 vs. FULC: $6.36)
Brand notoriety: CRVS and FULC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRVS: 57% vs. FULC: 64%
Market capitalization -- CRVS: $303.06M vs. FULC: $343.31M
CRVS [@Biotechnology] is valued at $303.06M. FULC’s [@Biotechnology] market capitalization is $343.31M. The market cap for tickers in the [@Biotechnology] industry ranges from $335.78B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRVS’s FA Score shows that 0 FA rating(s) are green whileFULC’s FA Score has 1 green FA rating(s).

  • CRVS’s FA Score: 0 green, 5 red.
  • FULC’s FA Score: 1 green, 4 red.
According to our system of comparison, FULC is a better buy in the long-term than CRVS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRVS’s TA Score shows that 5 TA indicator(s) are bullish while FULC’s TA Score has 5 bullish TA indicator(s).

  • CRVS’s TA Score: 5 bullish, 5 bearish.
  • FULC’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, FULC is a better buy in the short-term than CRVS.

Price Growth

CRVS (@Biotechnology) experienced а -12.67% price change this week, while FULC (@Biotechnology) price change was -6.88% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.32%. For the same industry, the average monthly price growth was +13.75%, and the average quarterly price growth was +8.90%.

Reported Earning Dates

CRVS is expected to report earnings on Aug 12, 2025.

FULC is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+7.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FULC($343M) has a higher market cap than CRVS($303M). FULC YTD gains are higher at: 35.319 vs. CRVS (-26.542). FULC has higher annual earnings (EBITDA): -8.94M vs. CRVS (-31.13M). FULC has more cash in the bank: 227M vs. CRVS (44.2M). CRVS has less debt than FULC: CRVS (1.15M) vs FULC (8.11M). FULC has higher revenues than CRVS: FULC (80M) vs CRVS (0).
CRVSFULCCRVS / FULC
Capitalization303M343M88%
EBITDA-31.13M-8.94M348%
Gain YTD-26.54235.319-75%
P/E RatioN/AN/A-
Revenue080M-
Total Cash44.2M227M19%
Total Debt1.15M8.11M14%
FUNDAMENTALS RATINGS
CRVS vs FULC: Fundamental Ratings
CRVS
FULC
OUTLOOK RATING
1..100
3472
VALUATION
overvalued / fair valued / undervalued
1..100
65
Fair valued
26
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9889
PRICE GROWTH RATING
1..100
4438
P/E GROWTH RATING
1..100
98100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FULC's Valuation (26) in the null industry is somewhat better than the same rating for CRVS (65) in the Pharmaceuticals Major industry. This means that FULC’s stock grew somewhat faster than CRVS’s over the last 12 months.

FULC's Profit vs Risk Rating (100) in the null industry is in the same range as CRVS (100) in the Pharmaceuticals Major industry. This means that FULC’s stock grew similarly to CRVS’s over the last 12 months.

FULC's SMR Rating (89) in the null industry is in the same range as CRVS (98) in the Pharmaceuticals Major industry. This means that FULC’s stock grew similarly to CRVS’s over the last 12 months.

FULC's Price Growth Rating (38) in the null industry is in the same range as CRVS (44) in the Pharmaceuticals Major industry. This means that FULC’s stock grew similarly to CRVS’s over the last 12 months.

CRVS's P/E Growth Rating (98) in the Pharmaceuticals Major industry is in the same range as FULC (100) in the null industry. This means that CRVS’s stock grew similarly to FULC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRVSFULC
RSI
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
81%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
75%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 9 days ago
79%
Bullish Trend 14 days ago
86%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
88%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
CRVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FULC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GTSRX22.920.12
+0.53%
Invesco Small Cap Growth R
FHEAX16.630.05
+0.30%
Fidelity Advisor Real Estate A
CSPIX14.910.03
+0.20%
Calvert Global Small-Cap Equity I
TIIRX26.31-0.04
-0.15%
Nuveen Core Equity A
JRSSX11.94-0.02
-0.17%
JH Adaptive Risk Mgd U.S. Eq S

CRVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRVS has been loosely correlated with SYRE. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if CRVS jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRVS
1D Price
Change %
CRVS100%
-0.25%
SYRE - CRVS
37%
Loosely correlated
-0.66%
TERN - CRVS
35%
Loosely correlated
+2.56%
VKTX - CRVS
34%
Loosely correlated
-0.57%
IPSC - CRVS
34%
Loosely correlated
-0.81%
FULC - CRVS
34%
Loosely correlated
-1.09%
More

FULC and

Correlation & Price change

A.I.dvisor indicates that over the last year, FULC has been loosely correlated with SLS. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if FULC jumps, then SLS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FULC
1D Price
Change %
FULC100%
-1.09%
SLS - FULC
48%
Loosely correlated
+0.64%
ANNX - FULC
40%
Loosely correlated
N/A
VRDN - FULC
39%
Loosely correlated
+1.11%
MLTX - FULC
34%
Loosely correlated
N/A
ITOS - FULC
34%
Loosely correlated
-0.20%
More